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Admission creatine kinase as a prognostic marker in acute myocardial infarction
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Abstract
Objectives: To investigate the prognostic significance of creatine kinase (CK) in Pakistani patients suffering from
acute myocardial infarction (AMI) and to find out if CK combined with troponin T (TnT) could be a better predictor
for long-term adverse cardiac event. 
Methods: One hundred and eighty six consecutive patients with AMI who were eligible for streptokinase (SK)
treatment were included in this prospective cohort study. The relationship between their serum/plasma CK and TnT
levels at the time of admission and clinical outcome was investigated over a mean follow up of 24.12 ± 3.75 months.
Results: Admission CK was found to be associated with subsequent cardiac event and mortality (P< 0.01 and
P< 0.04 respectively). Admission CK was also mildly associated with time interval between onset of symptoms
to SK treatment (correlation coefficient 'r' = 0.23). Odds of encountering a cardiac event in AMI patients with
above-normal CK levels (adjusted for gender) were 3.46 times higher than the odds in patients with normal CK
levels. Similarly, odds of mortality in patients with positive TnT were 4.6 times the odds in patients with negative
TnT. The two biochemical markers, CK and TnT, together did not provide any further information about prognosis
of the disease. 
Conclusion: Admission CK is a better prognostic marker for a subsequent cardiac event, while TnT is a better
predictor of mortality over a mean follow up of nearly 2 years. Together, they do not improve predictability of an
adverse cardiac event (JPMA 59:819; 2009).
Introduction
Creatine kinase (CK) is an enzyme that is abundantly
present in myocardial tissue. After the onset of symptoms of
acute myocardial infarction (AMI), circulating levels of CK
begin to increase within a few hours (3-12 hours) and after
reaching a peak fall to normal ranges within 24-36 hours.1
Therefore, it is a sensitive marker of myocardial infarction
(MI) but has relatively low specificity because of presence of
CK in skeletal muscles.
If CK in an AMI patient is at a low level in serum at
the time of admission, it indicates minimal amount of
myocardial damage, and the possibility of successful
treatment exists as a result of which mortality and morbidity
could be decreased.2
Although now more new sensitive and more specific
markers are available, CK is still widely used in developing
countries like Pakistan for confirming the diagnosis of AMI.
Recent clinical data have suggested that CK concentration in
serum at the time of presentation (admission CK) is an
independent predictor for the short and long term cardiac
outcomes.3-5 However, most of the studies on CK related to
prognosis have been reported from the West. Reports from the
developing world, especially from South Asian region,
regarding the prognostic value of CK in AMI are scarce. Apart
from one small study in India and another one from the Aga
Khan University Hospital (AKUH), Karachi, Pakistan, there is
hardly any report on prognostic significance of admission CK
in AMI patients in this part of the world.6,7
The purpose of this study was to examine the
relationship of admission CK level in serum and its prognostic
value in Pakistani patients suffering from AMI, and to find out
if CK along with troponin T (TnT) could be of added value in
predicting prognosis of the disease.
Patients and Methods
One hundred and eighty six consecutive AMI patients
(146 males; 40 females; mean age 56 ± 0.8 years) requiring
thrombolytic therapy with streptokinase (SK) were included
in this prospective cohort study. They were admitted to the
Coronary Care Unit of AKUH from October 1998 to October,
2001. AMI was diagnosed on the basis of clinical history,
electrocardiogram (ECG) and biochemical data. All these
patients were offered SK treatment (1.5 million units over a
period of 60 minutes). After discharge from the hospital, a
follow up from 18 months to 30 months was carried out.
The study had been approved by the Ethics Review
Committee of the Institution. 
Blood collection:
At the time of admission, 10 ml blood was collected
and half of it was transferred to a plain vacutainer tube and the
rest to another tube containing 3.8% sodium citrate as anti-
coagulant. Plasma and serum were removed by centrifugation
of two tubes at 1500xg.
Determination of CK and troponion t (TnT):
CK activity in serum and plasma concentration of TnT
were determined using commercially available kits (Roche
Diagnostic Ltd, Sussex, UK). While CK values were
described as IU/l (normal values for males < 174 IU/l and for
females < 140 IU/l), TnT values were reported as TnT positive
if the value was above 0.1ng/ml, or TnT negative when the
value it was below 0.1 ng/ml.
Clinical outcomes:
Follow up information was collected by telephone and
review of the medical records of patients with a mean ± SD
follow up of 24.12 ± 3.75 months. The primary end point was
information regarding mortality, reinfarction, or
revascularization. For analysis, any one of these events was
recorded as a cardiac event, however, mortality was included
in the analysis as an independent outcome as well. Forty-five
patients were lost to the follow up.
Statistical analysis:
Statistical analyses were done with the help of SPSS®
(Statistical Package for Social Sciences) version 13.0 for
Windows® (Apache Software Foundation, USA). Means
were expressed as means ± S.E. (standard error). Comparison
of distribution of frequencies of cardiac events and mortality
with respect to normal and above-normal levels of CK was
carried out by test of association using chi square. Independent
samples t-test was used to compare distribution of CK levels
between patients with cardiac event and patients with no
cardiac event during the follow up. Similarly, mean values
regarding distribution of time from symptoms to SK treatment
between patients experiencing a cardiac event and those
experiencing no cardiac event during the follow up were
compared using Independent samples t-test. Logistic
regression was used to relate above-normal and normal levels
of CK and TnT positivity and TnT negativity with clinical
outcomes. A P-value less than 0.05 was considered significant.
Results
Of the 186 patients studied, there were 146 males and
40 females. The mean age was 56 ± 08 years. Prior history of
MI was present in 75% patients. The mean time interval
between onset of symptoms and thrombolytic treatment was
188 ± 9 minutes. Regarding MI location, 40% had anterior,
while 35% had inferior and/or posterior location. The other
25% were those where ECG changes were not confined to any
one territory. 
Distribution of frequencies of cardiac events and
mortality in AMI patients with normal and above-normal
levels of CK is shown in Table-1. A comparison of these
outcome frequencies in two groups of patients (one group with
normal CK levels and another group with above-normal CK
levels) revealed that this marker of myocardial necrosis is
associated with both cardiac events as well as mortality.
To study the association (if any) between time from
onset of symptoms to SK treatment and admission CK levels,
the mean time values in group of patients with normal CK and
the group of patients with above-normal CK were statistically
analyzed by Independent samples t-test. The mean time (224
± 20 minutes) in the group with above-normal CK was higher
(P<0.001) than the mean time (156 ± 8 minutes) in the group
with normal CK. Strength of association was further analyzed
by Spearman's correlation test (non-parametric correlation),
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and a mild association between admission CK and time
between onset of symptoms to SK treatment was found
(correlation coefficient "r"=0.23). This indicates that greater
the time interval before treatment, higher would be the levels
of admission CK.
The relationship of time from onset of symptoms to
SK treatment with clinical outcome (both cardiac event and
mortality) in AMI patients, showed that the mean time interval
from onset of symptoms to SK treatment was higher in the
group of patients who died (219 ± 32 min) than the time
interval in the group which experienced at least one cardiac
event (197 ± 13 min). However, the two values when
compared by Independent samples t-test were not found to be
statistically significant (P = 0.093).
It is important to mention that though some of the
patients experienced more than one cardiac event
(reinfarction, revascularization or mortality), yet for analysis
purposes, for each patient these were entered as at least one
cardiac event. Therefore, 65.2% of AMI patients (n=92) had at
least one cardiac event. Mortality was taken as an independent
outcome as well and 14.2% of patients (n=20) died over a
mean follow up of 24 months.
Mean admission CK level, however, in patients with at
least one cardiac event was found to be significantly higher
than the mean level in patients who experienced no cardiac
event during the follow up time (P = 0.04; Table-2). This
suggests that admission CK could be of prognostic value at
least in terms of future risk of a cardiac event.
To see if the admission TnT levels add to the
prognostic value of admission CK, the values of admission
TnT and admission CK versus clinical outcome (in terms of
cardiac event and mortality) were analyzed in a logistic
regression model. The logistic regression model included 121
patients of which both admission CK and admission troponin
t values were available. Table-3 shows that although TnT is a
better prognostic marker for mortality (odds ratio 4.6), but CK
was a better predictor of any cardiac event (odds ratio 3.46).
The two biochemical markers together did not add to the
prognosis of the disease.
Discussion
CK is a sensitive marker of myocardial necrosis.
Compared to other biochemical markers, it is widely used for
diagnostic purposes in many developing countries due to its
high sensitivity and being more cost-effective than others.1 It
has been reported earlier that TnT is an independent risk
predictor of future deaths and MI in acute coronary
syndrome.7,8 The mean follow up times in both of these
studies were 13 months and 18 months, respectively. In the
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Table-1: Distribution of frequencies of cardiac events and mortality
in patients with AMI with normal and above-normal levels of CK.
Clinical outcome Normal CK* Above-normal CK* P**
(n=88) (n=53)
Number (%) Number (%)
Cardiac event (n=92) 50(57) 42(79) 0.01
Mortality (n=20) 8(40) 12(60) 0.044
*CK values were adjusted for gender.
**Based on test of association using chi-square.
Table-3: Odds ratios (OR) and 95% confidence interval (CI) of cardiac event and mortality by admission CK and admission troponin T.
Variable Clinical outcome at follow up
Subjects with Subjects with no cardiac OR* Mortality No Mortality OR*
cardiac event (n) event (n) (95% CI) (n) (n) (95% CI)
(n = 73) (n = 48) (n=18) (n=89)
CK
- Above-normal
(n = 43) 33 10 3.46(1.37-8.78) 10 28 1.44**(0.44-4.69)
- Normal
(n = 78) 40 38 1(Ref) 8 61 1(Ref)
Troponin T
-Positive (n=32) 21 11 0.78**(0.3-2) 11 20 4.62(1.4-15.1)
-Negative (n=89) 52 37 - 7 69 1(Ref)
*OR and CI were determined by applying logistic regression.
**Non-significant.
Note: A cardiac event refers to mortality or reinfarction or revascularization in one patient.
Logistic regression model included those subjects with both values of admission CK and admission TnT (n=121).
Table-2: Distribution of serum concentrations of admission
CK in AMI patients with and without cardiac event.
Mean ± SE
AMI patients N CK (admission) P*
(IU/l)
With no cardiac event 49 197 ± 42 0.04With cardiac event 92 434 ± 82
*P-value was obtained by comparing means values in the group of patients
experiencing no cardiac event vs those who experienced a cardiac event by
Independent samples t-test.
present study, the focus was on admission CK along with
admission TnT for their prognostic role in AMI patients over
a mean follow up time of nearly 2 years. This current data not
only substantiates the previous findings regarding role of
admission TnT in predicting cardiac death, but also provides
evidence towards the role of admission CK in predicting the
risk of future cardiac events, such as reinfarction, requirement
of revascularization and mortality. 
Gender was not identified to be associated with
clinical outcome (cardiac event or mortality). This is in line
with an earlier report from our hospital.8 A mild positive
association between admission CK levels and time interval
between onset of symptoms to SK treatment is indicative of
degree of cell damage (reflected by CK release) as a function
of time. It also points towards a better prognosis if the time
interval between onset of symptoms to SK treatment is
reduced as it would be accompanied by lower levels of CK.
Results of this study indicate that admission TnT is a
better predictor of mortality (OR 4.62) and conforms well with
those reported by Ohmen et al,9 who have also showed that
TnT levels were strongly associated with mortality (P<0.001)
compared to CK-MB (P=0.03).
Savonitto et al3 in a large study on 11,725 patients with
a 6-month follow up have reported that even minor CK
elevations appear to have important and independent
prognostic implications. Pierard et al10 have emphasized that
even a low peak serum level of CK would be associated with
higher mortality over a follow up of 3 years. All these reports
point towards the prognostic significance of CK in AMI.
Results of the present study corroborate well with these
reports and admission CK does appear to have a prognostic
value in Pakistani AMI patients.
Combination of markers of myocardial necrosis, such
as admission TnT (or troponin I) along with admission CK
would be expected to have more prognostic information
compared to a single marker. In a recent study, Szmanski et al5
have shown that mortality at 30 days in acute coronary
syndrome was higher in patients with all three markers
increased than in patients with other combinations. Similarly,
in a large study on 970 patients with non-ST elevation acute
myocardial syndromes with elevated CK along with positive
TnT, showed worst prognosis compared to those with one
positive biomarker.11 In the present study, we did not find any
additional benefit of including admission TnT to admission
CK values in predicting mortality or future cardiac events in
AMI patients over a mean follow up of 24.12 ± 3.75 months.
However, a prospective study using a large sample size over a
long follow up time would be required to clarify whether
combination of markers would be superior to a single marker
in predicting the risk of future cardiac events in AMI patients.
Conclusion
Admission CK is a better prognostic marker for a
combined end point of mortality, repeat MI and
revascularization, whereas admission TnT is a stronger
predictor of mortality in AMI patients over a mean ± SD
follow up of 24.12 ± 3.75 months. Together, they do not
improve predictability of adverse cardiac event.
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